Fernstad R, Sköldefors H, Pousette A, Groth C G, Tydén G, Ost L, Lindholm A, Carlström K
Department of Surgery, Sabbatsberg Hospital, Stockholm, Sweden.
Pancreas. 1989;4(1):44-52.
Pancreas-specific protein (PASP) is a recently isolated and partially characterized major protein in the human pancreas. It has not been described previously. Serum levels of PASP and amylase were analyzed in 21 patients subjected to combined renal and segmental pancreatic transplantation with both organs obtained from the same donor and in eight kidney transplant patients. In the pancreas transplant patients, PASP and amylase levels were elevated in episodes of graft pancreatitis. With chronic graft rejection, PASP rose to high levels long before other indications. In episodes of renal rejection, the levels of PASP, but not always of amylase, were elevated on several occasions. They decreased after antirejection therapy. This may indicate accompanying pancreatic graft rejection. PASP and amylase levels were stable in kidney transplant patients and were not affected by serum creatinine levels, renal rejection, or antirejection therapy. The results support earlier observations that renal rejection in combined pancreas and renal transplant patients may or may not be accompanied by a rejection process in the pancreatic graft. PASP may be the means by which to tell when the pancreatic graft is involved.
胰腺特异性蛋白（PASP）是一种最近从人胰腺中分离出来且部分特性已明确的主要蛋白质。此前尚未有过相关描述。对21例接受肾和节段性胰腺联合移植的患者（两个器官均来自同一供体）以及8例肾移植患者的血清PASP和淀粉酶水平进行了分析。在胰腺移植患者中，移植性胰腺炎发作时PASP和淀粉酶水平升高。在慢性移植排斥反应中，PASP早在出现其他指征之前就升至高水平。在肾排斥反应发作时，PASP水平有几次升高，但淀粉酶水平并非总是如此。抗排斥治疗后它们会下降。这可能表明伴有胰腺移植排斥反应。肾移植患者的PASP和淀粉酶水平稳定，不受血清肌酐水平、肾排斥反应或抗排斥治疗的影响。这些结果支持了早期的观察结果，即胰腺和肾联合移植患者的肾排斥反应可能伴有也可能不伴有胰腺移植的排斥过程。PASP可能是判断胰腺移植是否受累的一种手段。
